Business Wire (press release)

Share

SAN DIEGO & COLOGNE, Germany--(BUSINESS WIRE)--ACEA Biosciences (ACEA), a pioneer and leader in label-free real-time cell analysis instrumentation, and Ncardia, a leading expert in human cardiovascular stem cell technology, disease modelling and cell-based assay products and services, announced today that they have established a global partnership...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company pioneering the development of medicines to control the expression of disease-driving genes, today announced that it has identified alterations in regulatory regions of the genome in immune, tumor and stromal cells isolated from pancreatic cancer...

TAMPA, Fla.--(BUSINESS WIRE)--Minneamrita today announced that an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for a Phase 1 trial of an oral formulation of the company's Minnelide for patients with advanced cancers is now active. The first patient to participate in this exciting clinical trial received...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company pioneering the discovery and development of medicines to control the expression of disease-driving genes, today announced that the Company’s drug discovery research in immuno-oncology will be highlighted in an oral presentation at the American...

DUBLIN--(BUSINESS WIRE)--The "Innovative Solutions for Drug Discovery and Development" report has been added to Research and Markets' offering. The Drug Discovery TechVision Opportunity Engine (TOE) reports and analyzes about the latest developments in drug discovery and therapeutics, thereby providing an opportunity to acquire strategic insights...

DUBLIN--(BUSINESS WIRE)--The "Behavioral Disorders Drug Development Pipeline Review, 2017" report has been added to Research and Markets' offering. The report, "Behavioral Disorders Drug Development Pipeline Review, 2017" provides an overview of the behavioral disorders pipeline landscape. The report provides comprehensive information on the...

BOULDER, Colo.--(BUSINESS WIRE)--Clovis Oncology (NASDAQ: CLVS) announced today that the company has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for rucaparib as maintenance treatment of patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a...

Business Wire (press release)

 •  September 19

VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (“Zymeworks”), (NYSE: ZYME; TSX: ZYME) a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation bispecific and multifunctional biotherapeutics, today announced that Merck (known as MSD outside the US and Canada) has...

Business Wire (press release)

 •  September 19

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration’s (FDA) Oncologic Drug Advisory Committee (ODAC) voted 6 in favor and 6 against the benefit-risk profile for SUTENT® (sunitinib) as adjuvant treatment of adult patients at high risk of recurrent renal cell carcinoma (RCC) after nephrectomy...

Business Wire (press release)

 •  September 14

ANN ARBOR, Mich.--(BUSINESS WIRE)--Michigan’s second event to showcase the state’s academic drug R&D activities will be held on October 10, 2017 and hosted by Wayne State University. Tweet this The “Cutting Edge / Drug Discovery & Development in Michigan Symposium” will feature how new therapeutic entities are being discovered and advanced from...